EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

Gee Young Lee, Mohamed Mubasher, Tamra S. McKenzie, Nicole C. Schmitt, Merry E. Sebelik, Carrie E. Flanagan, Badi El Osta, Maya B. Cothran, Hadiyah-Nicole Green

Onco · 2021

DOI: 10.3390/onco1020007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Onco, 2021. Verfasst von Gee Young Lee und 8 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Laboratory Research and Development Service of the VA Office of Research and Development, National Center for Advancing Translational Sciences of the National Institutes of Health, National Cancer Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability.

Results

The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively.

Conclusion

LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.

Förderung

  • Biomedical Laboratory Research and Development Service of the VA Office of Research and Development
  • National Center for Advancing Translational Sciences of the National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Lee, G. Y., Mubasher, M., McKenzie, T. S., Schmitt, N. C., Sebelik, M. E., Flanagan, C. E., Osta, B. E., Cothran, M. B., & Green, H. (2021). Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer. Onco. https://doi.org/10.3390/onco1020007

Vancouver

Lee GY, Mubasher M, McKenzie TS, Schmitt NC, Sebelik ME, Flanagan CE, et al. Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer. Onco. 2021. doi:10.3390/onco1020007

BibTeX
@article{Lee2021,
  author = {Lee, Gee Young and Mubasher, Mohamed and McKenzie, Tamra S. and Schmitt, Nicole C. and Sebelik, Merry E. and Flanagan, Carrie E. and Osta, Badi El and Cothran, Maya B. and Green, Hadiyah-Nicole},
  title = {Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer},
  journal = {Onco},
  year = {2021},
  doi = {10.3390/onco1020007}
}
Kostenlos starten →